Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E80.13 EPS (ttm)1.65 Insider Own0.40% Shs Outstand227.97M Perf Week-3.92%
Market Cap30.09B Forward P/E23.74 EPS next Y5.56 Insider Trans-12.98% Shs Float222.77M Perf Month15.20%
Income373.20M PEG4.66 EPS next Q1.25 Inst Own98.20% Short Float2.49% Perf Quarter9.69%
Sales2.95B P/S10.18 EPS this Y-79.50% Inst Trans0.10% Short Ratio1.72 Perf Half Y3.67%
Book/sh37.93 P/B3.48 EPS next Y20.01% ROA3.10% Target Price167.60 Perf Year-15.14%
Cash/sh5.76 P/C22.92 EPS next 5Y17.19% ROE4.80% 52W Range109.12 - 162.65 Perf YTD7.86%
Dividend- P/FCF51.77 EPS past 5Y5.10% ROI1.60% 52W High-18.86% Beta1.40
Dividend %- Quick Ratio2.20 Sales past 5Y36.90% Gross Margin91.60% 52W Low20.94% ATR5.30
Employees2924 Current Ratio2.50 Sales Q/Q19.90% Oper. Margin23.90% RSI (14)52.47 Volatility2.42% 3.49%
OptionableYes Debt/Eq0.38 EPS Q/Q151.40% Profit Margin13.50% Rel Volume0.57 Prev Close134.35
ShortableYes LT Debt/Eq0.34 EarningsFeb 16 BMO Payout0.00% Avg Volume3.23M Price131.97
Recom2.00 SMA200.67% SMA505.72% SMA2000.64% Volume1,848,323 Change-1.77%
Dec-22-16Reiterated RBC Capital Mkts Outperform $188 → $187
Dec-15-16Initiated Oppenheimer Perform
Dec-13-16Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-03-16Initiated Deutsche Bank Buy $164
Oct-28-16Upgrade Goldman Neutral → Buy
Oct-28-16Upgrade FBR & Co. Underperform → Mkt Perform $92 → $130
Oct-28-16Reiterated Wedbush Neutral $132 → $135
Sep-23-16Initiated Wedbush Neutral $132
Sep-16-16Reiterated FBR & Co. Underperform $82 → $92
Sep-15-16Initiated FBR & Co. Underperform $82
Jul-29-16Reiterated Stifel Buy $195 → $182
Jul-29-16Reiterated Barclays Equal Weight $165 → $150
Jul-13-16Reiterated SunTrust Buy $220 → $197
Jul-13-16Initiated RBC Capital Mkts Outperform $188
Jul-11-16Upgrade Credit Suisse Neutral → Outperform $186 → $165
Jun-27-16Upgrade Citigroup Neutral → Buy
May-09-16Reiterated Barclays Equal Weight $175 → $180
Mar-08-16Downgrade Robert W. Baird Outperform → Neutral $221 → $170
Feb-25-16Initiated Citigroup Buy $165
Feb-04-16Reiterated UBS Buy $222 → $200
Jan-14-17 09:33AM  [$$] Drugmakers alarmed by Trump pricing threat at Financial Times
Jan-13-17 10:50PM  ALEXION 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Alexion Pharmaceuticals, Inc. (ALXN) Business Wire
10:10AM  FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) & Lead Plaintiff Deadline - January 17, 2017 GlobeNewswire
Jan-12-17 05:02PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. - ALXN PR Newswire
06:58AM  Trump takes aim at pharma
Jan-11-17 12:36PM  Here Is Why Red-Hot Alexion Is Only Suitable for Risk Takers Now
10:07AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline - January 17, 2017 Accesswire
09:35AM  JPMorgan Makes Big Changes to US Analyst Focus List for January 24/7 Wall St.
08:47AM  Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU
Jan-10-17 01:04PM  ALEXION PHARMACEUTICALS INC Financials
10:45AM  Alexion Seeks Expanded Use for Soliris in US and EU at Investopedia
08:15AM  Blog Coverage Alexion Pharma Applies for US and EU Marketing Approval of Refractory Generalized Myasthenia Gravis Medicine Accesswire
Jan-09-17 05:30PM  Mysterious $5 Billion Biotech Firm Moderna Lays Out Drug Pipeline at Forbes
03:55PM  Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference
03:30PM  Alexion Blood Disorder Meds Wins Orphan Drug Status at Investopedia
02:32PM  Alexion CEO: 'We're moving on' from shakeup
01:33PM  Bullish and Bearish Reversals in the Market
10:42AM  Here's Why Alexion Pharmaceuticals, Inc. Stock Gave Up 36% in 2016 at Motley Fool
10:25AM  Lawsuit for Investors in Shares of Alexion Pharmaceuticals, Inc. (ALXN) Announced by Shareholders Foundation Accesswire
08:15AM  Alexion Blood Disorder Drug Gets Orphan Designation in U.S.
06:30AM  Alexion Submits U.S. and EU Applications Seeking Approval of Soliris® (Eculizumab) as a Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG) Business Wire
Jan-07-17 05:15PM  INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm Accesswire
06:00AM  DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Alexion Pharmaceuticals, Inc. To Contact The Firm Business Wire
Jan-06-17 10:50PM  ALEXION SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. (ALXN) GlobeNewswire
10:10AM  Company News for January 06, 2017
10:02AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline - January 17, 2017 Accesswire
09:30AM  Alexion: Internal Probe Shows No Revenue Inflation at Investopedia
06:30AM  FDA Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Business Wire
Jan-05-17 04:51PM  3 ideas to improve waiting for your trades +9.50%
04:45PM  The Hot Stock: Alexion Rockets 9.5% at Barrons.com
04:32PM  Alexion Admits 'Inappropriate Conduct,' But Doesn't Restate Earnings
02:04PM  Alexion shares zoom higher as sales probe ends with no need for restatement, backs 2016 forecast at CNBC
01:48PM  ALXN ALERT: Rosen Law Firm Reminds Alexion Pharmaceuticals, Inc. Investors of Important January 17 Deadline in Class Action ALXN GlobeNewswire
01:06PM  Early movers: M, KSS, ALXN, GOOGL, WBA, MYL, MA & more at CNBC
11:40AM  Why These 5 Biopharma Stocks Are Making Massive Gains on Thursday
11:13AM  #1 issue top traders want to fix in 2017 on our prop desk
09:42AM  Stocks Open Narrowly Mixed; CEB Surges On Gartner Buyout
09:35AM  Stocks to Watch: Macy's, Kohl's, CEB, Sonic, Alexion Pharmaceuticals at The Wall Street Journal
08:59AM  Why Alexion Pharmaceuticals Is Overvalued at Forbes
08:52AM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
08:29AM  How Trump-related uncertainty is bringing out the health-care stock bears at MarketWatch
08:10AM  Alexion (ALXN) Stock Up on 10Q Filing; 2016 View Retained
06:30AM  Alexion to Present at the 35th Annual J.P. Morgan Healthcare Conference Business Wire
06:21AM  What Biotech Investors Can Expect From the J.P. Morgan Healthcare Conference 2017
12:10AM  PRESS DIGEST - Wall Street Journal - Jan 5
Jan-04-17 09:16PM  [$$] Alexion Says Management Improperly Pressured Staff to Boost Sales at The Wall Street Journal
07:07PM  Alexion says no need to revise earnings, shares rise Reuters
05:52PM  Alexion shares add to gains after hours as quarterly report filed at MarketWatch
05:21PM  Alexion Pharmaceuticals Files Form 10-Q for Third Quarter 2016 Business Wire
05:19PM  ALEXION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
03:34PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Alexion Pharmaceuticals, Inc. To Contact The Firm Before Lead Plaintiff Deadline PR Newswire
01:17PM  Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders According to a Recently Filed Class Action Business Wire
10:41AM  Alexions Soliris Fails In Kidney Transplant Study at Investopedia
10:03AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline - January 17, 2017 Accesswire
08:34AM  Alexion (ALXN): Will the Stock Continue to Suffer in 2017?
Jan-03-17 10:00PM  ALEXION SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. - (ALXN) PR Newswire
03:00PM  Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. Marketwired
11:53AM  ALXN INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Alexion Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017 PR Newswire
Jan-02-17 08:15AM  Alexion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ALXN-US : January 2, 2017
08:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alexion Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline ALXN GlobeNewswire
Jan-01-17 03:40PM  Here's Your Last Chance to Sell Shake Shack, 4 More 'Toxic Stocks' in 2016
Dec-30-16 03:06PM  Strensiq Boosted Alexion Pharmaceuticals Revenues in 2016
02:50PM  Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Alexion Pharmaceuticals, Inc. and Certain of Its Senior Executives PR Newswire
01:35PM  Will Soliris Drive Alexion Pharmaceuticals Revenues in 2017?
11:39AM  Alexion Pharmaceuticals Expects Strong Revenue Growth in 2016
07:37AM  Cystic Fibrosis Strategy: Will It Boost Vertexs Future Revenues?
Dec-29-16 03:05PM  Orkambi Is Still Strong Revenue Driver for Vertex Pharmaceuticals
01:14PM  Vertex Pharmaceuticals Expects Strong Revenue Growth in 2016
Dec-28-16 05:30PM  Safirstein Metcalf LLP Announces That A Class Action Lawsuit Has Been Filed Against Alexion Pharmaceuticals, Inc. - ALXN GlobeNewswire
10:55AM  Why United Therapeutics Expects Strong Revenue Growth
10:03AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline: January 17, 2017 Accesswire
Dec-27-16 12:19PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alexion Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 Business Wire
10:53AM  SHAREHOLDER ALERT: Class Action Lawsuit Against Alexion Announced by Holzer & Holzer Business Wire
08:53AM  Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead
Dec-23-16 10:50PM  ALEXION SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. - (ALXN) Marketwired
09:31PM  ALEXION (ALXN) ALERT: Johnson & Weaver, LLP Announces Filing of Class Action Complaint Against Alexion Pharmaceuticals, Inc.; Encourages all Investors to Contact the Firm for Information PR Newswire
06:36AM  Are These 3 Stocks the Biggest Comeback Opportunities of 2017? at Motley Fool
06:14AM  [$$] Alexion Stock May Be Worth $197 in Buyout at Barrons.com
Dec-22-16 05:29PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. ALXN GlobeNewswire +5.77%
10:51AM  Bad News Bashes Biotech Investors... Again at Motley Fool
10:42AM  How Alexion Pharmaceuticals Could Double in 2017 at Barrons.com
09:04AM  Health Care Sector Impacted Markets on December 21
08:25AM  RBC Likes Large Cap Biotech Leaders for 2017 at 24/7 Wall St.
08:03AM  Alexion Soliris Fails in Phase II/III Delayed Graft Function Study
Dec-21-16 04:39PM  Alexion Announces Phase Two Trial Failure, Falls Slightly After Hours
04:04PM  Alexion Announces Top-Line Results from Phase 2/3 PROTECT Study of Eculizumab (Soliris®) for the Prevention of Delayed Graft Function (DGF) After Kidney Transplantation Business Wire
12:11PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:36AM  Gilead Sciences: Buying Alexion Could Solve Both Their Problems at Barrons.com
10:35AM  What Are Analysts Saying about Horizon Pharma?
10:25AM  ALXN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Alexion Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017 Business Wire
Dec-20-16 05:46PM  SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm Accesswire
02:09PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Alexion Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit ALXN GlobeNewswire
12:36PM  Celgene Added To CS Focus List; "The Best House In The Biotech Neighborhood" at Barrons.com
Dec-19-16 05:25PM  Biogen Looks Within for Next CEO, Raising Concerns Top Outside Talent Passed on Job
01:25PM  Alexion Investors Want Answers at Motley Fool
12:40PM  10 Biotech Stocks Surprises for 2017And Not All of Them Are Bad at Barrons.com
Dec-17-16 08:04AM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
Dec-16-16 10:50PM  ALEXION SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. (ALXN) GlobeNewswire
08:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alexion Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALXN Accesswire
07:16PM  Robbins Arroyo LLP Is Investigating the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) on Behalf of Shareholders Business Wire
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BELL LEONARDDirectorJan 10Option Exercise22.901002,290403,719Jan 13 04:36 PM
BELL LEONARDDirectorJan 10Sale144.9910014,499403,619Jan 13 04:36 PM
BELL LEONARDDirectorJan 09Option Exercise22.904,853111,134408,472Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.9033448,397403,285Jan 09 05:21 PM
BELL LEONARDDirectorJan 09Sale144.934,853703,345403,619Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Option Exercise54.2620,1661,094,30426,539Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Option Exercise22.9034,210783,409438,497Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.4066891,783403,619Jan 09 05:21 PM
BELL LEONARDDirectorJan 05Sale137.5334,2104,704,730404,287Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale136.862,493341,2023,880Jan 09 05:21 PM
PARVEN ALVIN SDirectorJan 05Sale138.5420,1662,793,7526,373Jan 09 05:21 PM
Moriarty John BEVP & General CounselDec 12Sale118.611,044123,82950,181Dec 13 06:24 PM
Thiel CarstenEVP, Chief Commercial OfficerDec 09Sale130.002,308300,04030,433Dec 13 06:24 PM
Wagner Heidi LSVP, Global Government AffairsNov 14Sale115.10596,79131,936Nov 16 06:00 PM
BELL LEONARDDirectorNov 04Option Exercise22.9036,649839,262440,936Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale142.4066895,123404,287Nov 07 07:44 PM
BELL LEONARDDirectorNov 04Sale140.3436,6495,143,377404,287Nov 07 07:44 PM
BELL LEONARDDirectorOct 31Option Exercise22.901,30029,770406,589Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.3733445,214404,955Nov 02 07:22 PM
BELL LEONARDDirectorOct 31Sale135.281,300175,864405,289Nov 02 07:22 PM
Thiel CarstenEVP, Chief Commercial OfficerOct 14Sale120.284,584551,36432,741Oct 18 06:29 PM
Wagner Heidi LSVP, Global Government AffairsOct 03Sale122.4112014,68931,995Oct 05 05:25 PM
Thiel CarstenEVP, Chief Commercial OfficerOct 03Sale122.41293,55037,325Oct 05 05:25 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 13Sale129.003,000387,00037,354Sep 14 04:34 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 12Sale124.2022527,94540,354Sep 14 04:34 PM
Miller EdwardSVP, Chief Compliance OfficerSep 09Sale128.3236747,09316,519Sep 09 06:23 PM
Thiel CarstenEVP, Chief Commercial OfficerSep 06Sale125.941,000125,94040,579Sep 08 04:33 PM
O'Neill JulieEVP. Global OperationsSep 02Sale126.2965082,08935,384Sep 02 05:11 PM
Carmichael ClareEVP, Chief HR OfficerAug 30Sale127.761,000127,76038,577Sep 01 04:57 PM
PARVEN ALVIN SDirectorAug 22Option Exercise18.0115,000270,15021,373Aug 24 05:33 PM
PARVEN ALVIN SDirectorAug 22Sale136.5315,0002,047,9506,373Aug 24 05:33 PM
PARVEN ALVIN SDirectorAug 15Sale135.5170094,8576,373Aug 24 05:33 PM
Carmichael ClareEVP, Chief HR OfficerAug 08Sale137.1416522,62839,577Aug 10 06:23 PM
Moriarty John BEVP & General CounselAug 08Sale137.1413518,51451,225Aug 10 06:23 PM
Sinha VikasEVP & CFOAug 08Sale137.1427737,988178,463Aug 10 06:23 PM
Wagner Heidi LSVP, Global Government AffairsAug 08Sale137.1422230,44532,115Aug 10 06:24 PM
BELL LEONARDDirectorAug 08Sale137.141,010138,511405,289Aug 10 06:22 PM
Hallal DavidCEOAug 08Sale137.1433245,530189,266Aug 10 06:22 PM
Moriarty John BEVP & General CounselJun 13Sale135.72918124,59151,360Jun 14 04:50 PM
MACKAY MARTINEVP & Global Head of R&DMay 16Sale139.204,097570,28442,688May 18 04:36 PM
Wagner Heidi LSVP, Global Government AffairsMay 13Sale138.65537,34832,337May 13 05:48 PM
O'Neill JulieEVP. Global OperationsMar 02Sale149.5565197,35736,034Mar 04 06:21 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 29Sale138.9132945,70116,886Mar 01 06:33 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 29Sale138.91547,50141,579Mar 01 06:34 PM
BELL LEONARDDirectorFeb 29Sale138.923,995554,987742,197Mar 01 06:32 PM
Carmichael ClareEVP, Chief HR OfficerFeb 29Sale138.911,312182,25039,742Mar 01 06:32 PM
Moriarty John BEVP & General CounselFeb 29Sale138.911,201166,83352,278Mar 01 06:32 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 29Sale138.91905125,71443,799Mar 01 06:33 PM
Wagner Heidi LSVP, Global Government AffairsFeb 29Sale138.9154775,98432,390Mar 01 06:34 PM
Hallal DavidCEOFeb 29Sale138.932,014279,800191,012Mar 01 06:32 PM
Sinha VikasEVP & CFOFeb 29Sale138.911,122155,862178,740Mar 01 06:33 PM
MACKAY MARTINEVP & Global Head of R&DFeb 29Sale138.911,000138,91046,785Mar 01 06:34 PM
O'Neill JulieEVP. Global OperationsFeb 29Sale138.9166392,09736,685Mar 01 06:33 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 16Sale143.4918726,83336,633Feb 18 06:29 PM
Hallal DavidCEOFeb 08Sale138.053,946544,763173,026Feb 08 07:57 PM
Moriarty John BEVP & General CounselFeb 08Sale138.082,633363,57748,501Feb 08 07:58 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 08Sale138.071,474203,51844,704Feb 08 07:56 PM
BELL LEONARDDirectorFeb 08Sale138.0911,4741,584,442746,192Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 08Sale138.052,665367,91134,054Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 08Sale138.07942130,06629,937Feb 08 07:57 PM
O'Neill JulieEVP. Global OperationsFeb 08Sale138.07778107,41930,348Feb 08 07:55 PM
MACKAY MARTINEVP & Global Head of R&DFeb 08Sale138.091,966271,48140,785Feb 08 07:56 PM
Sinha VikasEVP & CFOFeb 08Sale137.613,890535,316171,862Feb 08 07:56 PM
Hallal DavidCEOFeb 05Sale141.636,722952,043176,972Feb 08 07:57 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 05Sale143.021,051150,31414,215Feb 08 07:57 PM
Moriarty John BEVP & General CounselFeb 05Sale143.451,969282,44751,134Feb 08 07:58 PM
Islam SaqibEVP, Chief Strat & Port. Off.Feb 05Sale143.481,970282,66146,178Feb 08 07:56 PM
BELL LEONARDDirectorFeb 05Sale143.122,136305,702757,666Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 05Sale141.761,993282,53836,719Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 05Sale143.14997142,70830,879Feb 08 07:57 PM
O'Neill JulieEVP. Global OperationsFeb 05Sale143.232,080297,91931,126Feb 08 07:55 PM
MACKAY MARTINEVP & Global Head of R&DFeb 05Sale141.562,005283,82342,751Feb 08 07:56 PM
Sinha VikasEVP & CFOFeb 05Sale143.501,954280,404175,752Feb 08 07:56 PM
Hallal DavidCEOFeb 04Sale143.8362990,469142,558Feb 08 07:57 PM
BELL LEONARDDirectorFeb 04Sale143.832,262325,338746,997Feb 08 07:56 PM
Carmichael ClareEVP, Chief HR OfficerFeb 04Sale143.8420729,77426,949Feb 08 07:57 PM
Wagner Heidi LSVP, Global Government AffairsFeb 04Sale143.8416924,30925,747Feb 08 07:57 PM
Sinha VikasEVP & CFOFeb 04Sale143.83703101,116165,943Feb 08 07:56 PM